Investing Port

P/S	71.56
P/BV	8.44
EV/EBITDA	-50.57
EBITDA	-0.13
Цена ао	125.88

Дата сделки	Дата раскрытия	Инсайдер	Тип	Цена	Объем	Количество	Доля до, %	Доля после, %	Документ
11.12.2020	11.12.2020	MCLAUGHLIN KEVIN F SVP, CFO and Treasurer	Продажа	125	387 500.00	3100	0	-0.01	ссылка
09.12.2020	11.12.2020	MCLAUGHLIN KEVIN F SVP, CFO and Treasurer	Продажа	125.03	484 116.00	3872	0	-0.01	ссылка
10.12.2020	11.12.2020	MCLAUGHLIN KEVIN F SVP, CFO and Treasurer	Продажа	125.12	62 560.00	500	0	0	ссылка

Institutions	Объем	Доля, %
Hennion & Walsh, Inc	200	0
Foresite Capital Management III, LLC	108630	0.18
Peroni Portfolio Advisors, Inc	300	0
Putnam Investment Management, LLC	381471	0.63
Fidelity Management & Research Company LLC	3487318	5.79
First Trust Portfolios L.P.	10365	0.02
Columbia Wanger Asset Management LLC	541172	0.9
Baron Capital Management Inc	845643	1.4
Principal Global Investors, LLC	227853	0.38
Fidelity SelectCo, LLC	2635961	4.37
Granahan Investment Management Inc	91177	0.15
Kennedy Capital Management	41541	0.07
Westend Sa	1400000	2.32
AXA Investment Managers UK Ltd	207067	0.34
Invesco Capital Management LLC	67344	0.11
Zeus Asset Management S.A.	1253	0
Artal Group S A	1400000	2.32
BlackRock Fund Advisors	1270397	2.11
Artisan Partners Holdings LP	531970	0.88
Prudential Retirement Services	174917	0.29
PMG Fonds Management AG	17200	0.03

ETF	Доля, %	Доходность за год, %
First Trust BuyWrite Income ETF	2.73
First Trust Hedged BuyWrite Income ETF	2.64

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.